{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T09:44:41Z","timestamp":1784454281818,"version":"3.55.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"23","funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou City Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y20211020"],"award-info":[{"award-number":["Y20211020"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Quercetin and apigenin are two common dietary flavonoids widely found in\nfoods and fruits. Quercetin and apigenin can act as the inhibitors of CYP450 enzymes, which may affect\nthe pharmacokinetics of clinical drugs. Vortioxetine (VOR), approved for marketing by the Food and\nDrug Administration (FDA) in 2013, is a novel clinical drug for treating major depressive disorder\n(MDD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to evaluate the effects of quercetin and apigenin on the metabolism of VOR\nin in vivo and in vitro experiments.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>Firstly, 18 Sprague-Dawley rats were randomly divided into three groups: control group\n(VOR), group A (VOR + 30 mg\/kg quercetin) and group B (VOR + 20 mg\/kg apigenin). We collected the\nblood samples at different time points before and after the final oral administration of 2 mg\/kg VOR. Subsequently,\nwe further used rat liver microsomes (RLMs) to investigate the half-maximal inhibitory concentration\n(IC50) of the metabolism of vortioxetine. Finally, we evaluated the inhibitory mechanism of two\ndietary flavonoids on VOR metabolism in RLMs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In animal experiments, we found AUC (0-\u221e) (area under the curve from 0 to infinity) and CLz\/F\n(clearance) to be obviously changed. Compared to controls, AUC (0-\u221e) of VOR in group A and group B\nwas 2.22 and 3.54 times higher, respectively, while CLz\/F of VOR in group A and group B was significantly\ndecreased down to nearly two-fifth and one-third. In in vitro studies, the IC50 value of quercetin and\napigenin in the metabolic rate of vortioxetine was 5.323 \u03bcM and 3.319 \u03bcM, respectively. Ki value of\nquercetin and apigenin was found to be 0.040 and 3.286, respectively, and the \u03b1Ki value of quercetin and\napigenin was 0.170 and 2.876 \u03bcM, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Quercetin and apigenin exhibited inhibitory effects on the metabolism of vortioxetine in vivo\nand in vitro. Moreover, quercetin and apigenin had a mixed mechanism on the metabolism of VOR in\nRLMs. Thus, we should pay more attention to the combination between these dietary flavonoids and VOR\nin the future clinical use.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230607104411","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:44:58Z","timestamp":1686203098000},"page":"3624-3630","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Dietary Flavonoids on the Metabolism of Vortioxetine and\nits Potential Mechanism"],"prefix":"10.2174","volume":"31","author":[{"given":"Yuxian","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital), The\nThird Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Basic Medicine College, Renji College\nof Wenzhou Medical University, Wenzhou, China"},{"name":"Basic Medicine College, Wenzhou Medical University, Wenzhou,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhize","family":"Ye","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Institute of Molecular Toxicology and Pharmacology, Wenzhou Medical\nUniversity, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyong","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Institute of Molecular Toxicology and Pharmacology, Wenzhou Medical\nUniversity, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of\nZhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital), The\nThird Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of\nZhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[{"name":"Procurement Department,\nThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2215-0366(21)00251-0","volume":"8","author":"Lu J.","year":"2021","unstructured":"Lu J.; Xu X.; Huang Y.; Li T.; Ma C.; Xu G.; Yin H.; Xu X.; Ma Y.; Wang L.; Huang Z.; Yan Y.; Wang B.; Xiao S.; Zhou L.; Li L.; Zhang Y.; Chen H.; Zhang T.; Yan J.; Ding H.; Yu Y.; Kou C.; Shen Z.; Jiang L.; Wang Z.; Sun X.; Xu Y.; He Y.; Guo W.; Jiang L.; Li S.; Pan W.; Wu Y.; Li G.; Jia F.; Shi J.; Shen Z.; Zhang N.; Prevalence of depressive disorders and treatment in China: A cross-sectional epidemiological study. Lancet Psychiatry  2021,8(11),981-990","journal-title":"Lancet Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1358\/dot.2013.49.12.2058448","volume":"49","author":"Dhir A.","year":"2013","unstructured":"Dhir A.; Vortioxetine for the treatment of major depression. Drugs Today  2013,49(12),781-790","journal-title":"Drugs Today"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.112.044610","volume":"40","author":"Hvenegaard M.G.","year":"2012","unstructured":"Hvenegaard M.G.; Bang-Andersen B.; Pedersen H.; J\u00f8rgensen M.; P\u00fcschl A.; Dalgaard L.; Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos  2012,40(7),1357-1365","journal-title":"Drug Metab Dispos"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"103136","DOI":"10.1016\/j.arabjc.2021.103136","volume":"14","author":"Xu R.","year":"2021","unstructured":"Xu R.; Luo S.; Lin Q.; Shao Y.; Chen C.; Ye X.; Inhibitory effect of propafenone on vortioxetine metabolism in vitro and in vivo. Arab J Chem  2021,14(5),103136","journal-title":"Arab J Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1007\/s10753-022-01645-w","volume":"45","author":"Vissenaekens H.","year":"2022","unstructured":"Vissenaekens H.; Grootaert C.; Raes K.; De Munck J.; Smagghe G.; Boon N.; Van Camp J.; Quercetin mitigates endothelial activation in a novel intestinal-endothelialmonocyte\/macrophage coculture setup. Inflammation  2022,45(4),1600-1611","journal-title":"Inflammation"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/molecules27092901","volume":"27","author":"Al-Khayri J.M.","year":"2022","unstructured":"Al-Khayri J.M.; Sahana G.R.; Nagella P.; Joseph B.V.; Alessa F.M.; Al-Mssallem M.Q.; Flavonoids as potential anti-inflammatory molecules: A review. Molecules  2022,27(9),2901","journal-title":"Molecules"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"110363","DOI":"10.1016\/j.cellsig.2022.110363","volume":"96","author":"Sang A.","year":"2022","unstructured":"Sang A.; Wang Y.; Wang S.; Wang Q.; Wang X.; Li X.; Song X.; Quercetin attenuates sepsis-induced acute lung injury via suppressing oxidative stress-mediated ER stress through activation of SIRT1\/AMPK pathways. Cell Signal  2022,96,110363","journal-title":"Cell Signal"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"943321","DOI":"10.3389\/fimmu.2022.943321","volume":"13","author":"Cui Z.","year":"2022","unstructured":"Cui Z.; Zhao X.; Amevor F.K.; Du X.; Wang Y.; Li D.; Shu G.; Tian Y.; Zhao X.; Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front Immunol  2022,13,943321","journal-title":"Front Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08923973.2022.2130076","volume":"2022","author":"Kuru Bekta\u015fo\u011flu P.","year":"2022","unstructured":"Kuru Bekta\u015fo\u011flu P.; Demir D.; Koyuncuo\u011flu T.; Y\u00fcksel M.; Peker Ey\u00fcbo\u011flu \u0130.; Karag\u00f6z K\u00f6ro\u011flu A.; Akak\u0131n D.; Y\u0131ld\u0131r\u0131m A.; \u00c7eliko\u011flu E.; G\u00fcrer B.; Possible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of mild traumatic brain injury: An investigation. Immunopharmacol Immunotoxicol  2022,2022,1-12","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2147\/DDDT.S249308","volume":"14","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Hua A.; Zhou Q.; Geng P.; Chen F.; Yan L.; Wang S.; Wen C.; Inhibitory effect of Lygodium root on the cytochrome P450 3A enzyme in vitro and in vivo. Drug Des Devel Ther  2020,14,1909-1919","journal-title":"Drug Des Devel Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/ptr.5220","volume":"28","author":"Rastogi H.","year":"2014","unstructured":"Rastogi H.; Jana S.; Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities. Phytother Res  2014,28(12),1873-1878","journal-title":"Phytother Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"8218","DOI":"10.1016\/j.arabjc.2020.09.056","volume":"13","author":"Gu E-M.","year":"2020","unstructured":"Gu E-M.; Shao Y.; Xu W-F.; Ye L.; Xu R.; UPLC-MS\/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions. Arab J Chem  2020,13(11),8218-8225","journal-title":"Arab J Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/DDDT.S160316","volume":"12","author":"He J.","year":"2018","unstructured":"He J.; Fang P.; Zheng X.; Wang C.; Liu T.; Zhang B.; Wen J.; Xu R.; Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo. Drug Des Devel Ther  2018,12,513-519","journal-title":"Drug Des Devel Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jpba.2016.05.029","volume":"128","author":"Huang Y.","year":"2016","unstructured":"Huang Y.; Zheng S.; Pan Y.; Li T.; Xu Z.; Shao M.; Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC\u2013MS\/MS: Application to their pharmacokinetic interaction study. J Pharm Biomed Anal  2016,128,184-190","journal-title":"J Pharm Biomed Anal"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","volume":"33","author":"Chen G.","year":"2013","unstructured":"Chen G.; Lee R.; H\u00f8jer A.M.; Buchbjerg J.K.; Serenko M.; Zhao Z.; Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig  2013,33(10),727-736","journal-title":"Clin Drug Investig"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/13880209.2022.2048862","volume":"60","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Liu Y.; Xie S.; Xu X.; Xu R.; Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC\u2013MS\/MS assay. Pharm Biol  2022,60(1),621-626","journal-title":"Pharm Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"105809","DOI":"10.1016\/j.ejps.2021.105809","volume":"161","author":"Aleksandar R.","year":"2021","unstructured":"Aleksandar R.; Milica P.K.; Gorana M.; Boris M.; Anastazija S.M.; Mladena L.P.; Sne\u017eana S.; Neboj\u0161a S.; Slobodan G.; Interaction between apigenin and sodium deoxycholate with raloxifene: A potential risk for clinical practice. Eur J Pharm Sci  2021,161,105809","journal-title":"Eur J Pharm Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/00498254.2020.1792002","volume":"50","author":"Bhutani P.","year":"2020","unstructured":"Bhutani P.; Rajanna P.K.; Paul A.T.; Impact of quercetin on pharmacokinetics of quetiapine: Insights from in-vivo studies in wistar rats. Xenobiotica  2020,50(12),1483-1489","journal-title":"Xenobiotica"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"S895","DOI":"10.4103\/0973-1296.224342","volume":"13","author":"Elbarbry F.","year":"2018","unstructured":"Elbarbry F.; Ung A.; Abdelkawy K.; Studying the inhibitory effect of Quercetin and Thymoquinone on human cytochrome P450 enzyme activities. Pharmacogn Mag  2018,13(Suppl. 4),S895-S899","journal-title":"Pharmacogn Mag"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1007\/s13197-014-1472-x","volume":"52","author":"Vijayakumar T.M.","year":"2015","unstructured":"Vijayakumar T.M.; Kumar R.M.; Agrawal A.; Dubey G.P.; Ilango K.; Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening. J Food Sci Technol  2015,52(7),4537-4543","journal-title":"J Food Sci Technol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3390\/molecules26103018","volume":"26","author":"Kond\u017ea M.","year":"2021","unstructured":"Kond\u017ea M.; Boji\u0107 M.; Tomi\u0107 I.; Male\u0161 \u017d.; Rezi\u0107 V.; \u0106avar I.; Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules  2021,26(10),3018","journal-title":"Molecules"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/00498254.2018.1478168","volume":"49","author":"Zhao Q.","year":"2019","unstructured":"Zhao Q.; Wei J.; Zhang H.; Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. Xenobiotica  2019,49(5),563-568","journal-title":"Xenobiotica"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230607104411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217734\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230607104411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:58:22Z","timestamp":1722412702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217734\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230607104411","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}